ADC Therapeutics finalises a $303M series E round

ADC Therapeutics finalises a $303M series E round

10.7.2019 – An additional $25 million investment from a U.S based institutional investor in ADC Therapeutic brings the company’s series E proceeds to $303 million. The biopharma company will continue to carry out its undertakings for its lead candidates ADCT-402 and ADCT-301.

read more…